2nd Quarter - Report

EISAI INC. for EISAI INC.

Firm
Client
Income
—
Expenses
$350,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Copyright/Patent/Trademark CPT

Ongoing discussions and updates on Amicus petition for certiori in Helsinn Healthcare SA v Teva Pharmaceuticals USA Inc., Teva Pharmaceutical Industries, Ltd.

LobbyistCovered position, as disclosed
TIMOTHY CLARK —

Contacted: Health & Human Services, Dept of (HHS); SENATE; HOUSE OF REPRESENTATIVES

Medicare/Medicaid MMM

Potential pharmaceutical reimbursement cuts (offsets) and potential inclusion of Medicare coverage of FDA-approved obesity drugs. H.R. 1953/S. 830 - Treat and Reduce Obesity Act of 2017 Revisions to Medicare reimbursement programs on obesity interventions Changes to reimbursement structure of Medicare Part D program H.R. 1892 Bipartisan Budget Act of 2018

LobbyistCovered position, as disclosed
TIMOTHY CLARK —

Contacted: SENATE; Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES

Bills named: H.R. 1892 (115th), H.R. 1953 (115th), S. 830 (115th)

Health Issues HCR

S. 204/H.R. 878 - Trickett Wendler Right To Try Act of 2017 S. 870 - Creating High-Quality Results and Outcomes Necessary to Improve Chronic (CHRONIC) Care Act of 2017 Regulatory and legislative health care issues, including the 340B program Issues related to the treatment of obesity Drug Cost and Pricing Issues related to the diagnosis and treatment of Alzheimer's Disease

LobbyistCovered position, as disclosed
TIMOTHY CLARK —

Contacted: SENATE; Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES

Bills named: H.R. 878 (115th), S. 204 (115th), S. 870 (115th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.